New combo aims to beat High-Risk leukemia and MDS
NCT ID NCT06802315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 38 adults aged 18 to 65. The goal is to see if this combination reduces the chance of relapse and graft-versus-host disease one year after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- total marrow irradiation, fludarabine, busulfan, cyclophosphamide
- What this could lead to
- If successful, this approach could improve survival and reduce relapse and graft-versus-host disease for people with high-risk blood cancers.
- What could go wrong
- This is a small, early-phase trial (38 people) with no control group, so results may not apply broadly. The intense conditioning carries risks like infection, organ damage, and graft failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can donor immune cells tame stem cell transplant risks?